Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)
China · Delayed Price · Currency is CNY 39.40
+0.57 (1.47%)
Sep 30, 2026, 3:00 PM CST
SHA:688091 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8,069 | 9,655 | 8,204 | 10,130 | 10,043 | 4,748 | |
Market Cap Growth | -32.71% | 17.68% | -19.01% | 0.86% | 111.52% | - |
Enterprise Value | 7,158 | 9,170 | 7,561 | 9,024 | 9,008 | 3,816 |
Last Close Price | 39.40 | 47.00 | 39.92 | 48.83 | 48.26 | 22.82 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 115.55 | 149.56 | 1176.22 | 62.70 | 70.31 | - |
PS Ratio | 25.09 | 30.55 | 47.28 | 28.12 | 42.57 | 1164.50 |
PB Ratio | 5.41 | 6.75 | 5.84 | 6.92 | 7.61 | 4.04 |
P/TBV Ratio | 5.52 | 6.89 | 5.87 | 6.96 | 7.66 | 4.07 |
P/FCF Ratio | - | - | - | 130.25 | 134.09 | - |
P/OCF Ratio | 164.82 | - | 208.04 | 117.03 | 90.66 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 22.26 | 29.01 | 43.57 | 25.05 | 38.18 | 935.90 |
EV/EBITDA Ratio | 132.71 | 164.79 | - | 53.89 | 77.72 | - |
EV/EBIT Ratio | 175.12 | 210.03 | - | 56.56 | 82.28 | - |
EV/FCF Ratio | - | - | - | 116.03 | 120.27 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.02 | - | 0.03 | - | 0.01 |
Debt / EBITDA Ratio | 0.46 | 0.45 | - | 0.26 | - | - |
Debt / FCF Ratio | - | - | - | 0.57 | - | - |
Net Debt / Equity Ratio | -0.61 | -0.28 | -0.48 | -0.82 | -0.85 | -0.80 |
Net Debt / EBITDA Ratio | -16.90 | -7.19 | 138.50 | -7.14 | -9.73 | 45.91 |
Net Debt / FCF Ratio | 33.27 | 2.68 | 16.53 | -15.38 | -15.06 | 18.03 |
Asset Turnover | 0.21 | 0.21 | 0.12 | 0.25 | 0.19 | 0.01 |
Inventory Turnover | 0.94 | 1.02 | 0.36 | 1.04 | 1.18 | 0.05 |
Quick Ratio | 13.02 | 8.15 | 18.27 | 13.30 | 39.18 | 45.80 |
Current Ratio | 13.84 | 9.17 | 19.68 | 13.59 | 40.17 | 47.08 |
Return on Equity (ROE) | 4.69% | 4.55% | 0.49% | 11.61% | 11.45% | -0.56% |
Return on Assets (ROA) | 1.65% | 1.83% | -0.66% | 6.81% | 5.36% | -2.31% |
Return on Invested Capital (ROIC) | 5.00% | 4.95% | -3.19% | 59.95% | 48.57% | -12.41% |
Return on Capital Employed (ROCE) | 2.70% | 3.00% | -1.10% | 10.90% | 8.30% | -2.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.85% | 0.67% | 0.08% | 1.59% | 1.42% | -0.08% |
FCF Yield | -0.34% | -1.55% | -0.50% | 0.77% | 0.75% | -1.09% |
Dividend Yield | - | - | - | 0.06% | 0.43% | - |
Payout Ratio | 0.44% | 0.11% | 713.87% | 26.87% | 0.34% | - |
Buyback Yield / Dilution | 18.81% | 13.23% | -46.80% | 23.24% | -32.68% | -2.51% |
Total Shareholder Return | 18.81% | 13.23% | -46.80% | 23.31% | -32.24% | -2.51% |